Frontlight ResearchEarly access
CompletedPhase 3
A 6-Month Extension Study of VMDN-003-2 to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
Key facts
- Who runs it
- Helixmith Co., Ltd.
- Where
- Chesterfield, Clearwater, Houston, Little Rock, Los Angeles, Manassas, McAllen, Norfolk, O'Fallon, Phoenix, Rapid City, Richmond, Sacramento, Springfield, Staten Island, and Waxahachie, United StatesSee the 16 sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 106 people enrolled
- Started
- 17 May 2021
- Ended
- 23 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Engensis
- Placebo
- Record updated
- 9 October 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Completed study VMDN-003-2 and consent to enroll in study VMDN-003-2b
Who cannot take part
- None
Where in United States
- Clinical Research ProfessionalsChesterfield, United States
- Innovative Research of West Florida, Inc.Clearwater, United States
- Nerve and Muscle Center of TexasHouston, United States
- Clinical Trials - Little RockLittle Rock, United States
- California Medical Clinic for HeadacheLos Angeles, United States
- Manassas Clinical Research CenterManassas, United States
- Futuro Clinical TrialsMcAllen, United States
- Eastern Virginia Medical SchoolNorfolk, United States
- Gateway Clinical Trials, LLCO'Fallon, United States
- Arizona Research CenterPhoenix, United States
- Health ConceptsRapid City, United States
- Dominion Medical AssociatesRichmond, United States
- Clinical Trials Research SacramentoSacramento, United States
- Foot & Ankle Center of IllinoisSpringfield, United States
- Richmond Behavioral AssociatesStaten Island, United States
- ClinPoint Trials LLCWaxahachie, United States
About the trial
What the trial wants to find out
To evaluate the durability of efficacy and long-term safety of intramuscular administration of Engensis or Placebo that was administered in the double-blind, randomized, VMDN-003-2 Placebo-controlled Phase 3 Study.
The 2 groups in the trial
- EngensisTreatment being tested
Patients who have received Engensis in protocol VMDN-003-2
- PlaceboPlacebo, for comparison
Patients who have received Placebo in protocol VMDN-003-2
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A 6-Month Extension Study Following Protocol VMDN-003-2 - An Adaptive, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess Engensis in Participants With Painful Diabetic Peripheral Neuropathy
- Record updated
- 9 October 2025